PPT-SQV and LPV-RTV in Treatment-Experienced Children HIV-NAT 017

HIVNAT 017 SQV and LPVRTV in TreatmentExperienced Children HIVNAT 017 Study Design Source Kosalaraksa P et al Pediatr Infect Dis J 200827 6238 SQV LPVRTV 3TC. Despite this signi64257cant progress the number of children becoming newly infected with HIV remains unacceptably high About 240 000 210 000280 000 children became infected with HIV in 2013 The risk of a mother living with HIV passing the virus to h . Easier for HCW’s to prescribe for . all. ages. Easier for caregivers to administer to infants . and children. Easier for infants and children to adhere. Easier to manage supply chain. Target Product Profile for . Susan M. Graham . Assistant Professor, Medicine and Global Health. Adjunct Assistant Professor, Epidemiology. Presentation prepared by: . Susan M. Graham. Last Updated: . October 29, 2014. Susan M. Graham, MD MPH PhD. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Kiat. . Ruxrungtham. Professor of Medicine, . Chulalongkorn University; and. HIV-NAT, Thai Red Cross AIDS Research Center. Three Decades of HIV/AIDS . Learning and the Future. Mid 1990. 1981. 2012 - 2014. M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA.  . 0-3 years. >3years and >10 kg.  . 1. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Kiat. . Ruxrungtham. Professor of Medicine, . Chulalongkorn University; and. HIV-NAT, Thai Red Cross AIDS Research Center. Three Decades of HIV/AIDS . Learning and the Future. Mid 1990. 1981. 2012 - 2014. Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017. Available HCV treatment DAAs. Epclusa. (. sofosbuvir. / . velpatasvir. ). Harvoni. (. sofosbuvir. / . ledipasvir. ). Zepatier. (. grazoprevir. / . 2 NRTIs in Treatment-Experienced. M97-765 Trial. Lopinavir. -RTV + . Nevirapine. + 2 NRTIs in Treatment-Experienced . M97-765: . Study Design. Source. : . Benson CA, et al. . J . Infect. . Dis. . 2002;185:599-607.. Virologically. Suppressed. OLE Trial. LPV-RTV + . 3TC vs. LPV. -RTV + 2 NRTIs. in . Virologically. Suppressed. OLE: . Study Design. Source: . Arribas. JR, et al. . Lancet Infect Dis. . 2015;15:. 785-92.. DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs. Dr. Sonalika’s Eye Clinic provide the best Conjunctivitis (Pink Eye) treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri